Compare INGN & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INGN | VTVT |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.4M | 148.7M |
| IPO Year | 2013 | 2015 |
| Metric | INGN | VTVT |
|---|---|---|
| Price | $6.30 | $35.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $11.25 | ★ $53.00 |
| AVG Volume (30 Days) | ★ 326.0K | 44.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $348,668,000.00 | N/A |
| Revenue This Year | $8.03 | N/A |
| Revenue Next Year | $7.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.86 | N/A |
| 52 Week Low | $5.34 | $14.00 |
| 52 Week High | $9.13 | $44.00 |
| Indicator | INGN | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 38.58 | 53.97 |
| Support Level | $5.97 | $34.29 |
| Resistance Level | $6.93 | $41.59 |
| Average True Range (ATR) | 0.38 | 2.22 |
| MACD | -0.10 | 0.64 |
| Stochastic Oscillator | 1.74 | 71.84 |
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.